Cosentyx is a biologic drug primarily used for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. It is a human monoclonal antibody that selectively binds and inhibits interleukin-17A (IL-17A) cytokine. The drug has found substantial adoption in recent years owing to its targeted mechanism of action and favorable safety profile compared to other biologics.
The global Cosentyx drug market is estimated to be valued at US$ 5.72 billion in 2025 and is expected to exhibit a CAGR of 7.5% over the forecast period 2025-2032.
Key Takeaways
Key players operating in the Cosentyx drug market are Novartis, Sandoz, Amgen.
The market offers significant opportunities in terms of increasing acceptance of biosimilar drugs and expanding therapeutic applications of IL-17 inhibitors. Advancements in biosimilar development are also expected to make Cosentyx more affordable in the coming years.
Market drivers
Cosentyx Drug Market Demand is increasing global prevalence of immune-mediated inflammatory diseases such as psoriasis and psoriatic arthritis is a major factor driving the demand for Cosentyx drug. According to estimates, approx. 125 million people worldwide suffer from psoriasis. Growing elderly population also contributes to the market growth as the risk of developing these conditions increases with age. In addition, rising awareness about newer treatment options and favorable reimbursement policies in developed regions further support the adoption of Cosentyx drug.
Key players operating in the Cosentyx drug market are Novartis, Sandoz, Amgen. Advancements in biosimilar development are also expected to make Cosentyx more affordable in the coming years. The market offers significant opportunities in terms of increasing acceptance of biosimilar drugs and expanding therapeutic applications of IL-17 inhibitors. Growing elderly population also contributes to the market growth as the risk of developing these conditions increases with age. In addition, rising awareness about newer treatment options and favorable reimbursement policies in developed regions further support the adoption of Cosentyx drug.
Current Challenges in Cosentyx Drug Market
The Cosentyx drug market is currently facing several challenges. Patent expiry of blockbuster drugs has resulted in loss of revenues for companies. This is prompting firms to focus on biosimilars and novel drugs to diversify their portfolios. Stiff competition from other drugs to treat psoriasis and psoriatic arthritis is also hampering market growth. High development costs of biologics coupled with lengthy approval timelines poses substantial risks for players. Rise of biosimilars once patents expire can erode market share of leading brands. Ensuring drug safety and efficacy through long term studies remains a key challenge given complex nature of biologics. Sustaining high R&D investments to develop new indications is testing financial capacities of companies.
SWOT Analysis
Strength: High efficacy and safety profile of Cosentyx for treatment of psoriasis and arthritis. Positive clinical trial data and regulatory approvals driving sales growth.
Weakness: Narrow product portfolio of company depends heavily on brand. Patent expiry and biosimilars competition post-patent expiration.
Opportunity: Large untreated patient population offers scope to expand market reach. New geographical markets and additional indications can boost future revenues.
Threats: Intense competition from other biologics and small molecules. pricing pressures from payers may limit price increases.
Geographical Regions
North America currently accounts for the largest share of the global Cosentyx drug market in terms of value. This is attributed to the strong presence of biopharmaceutical industry and availability of advanced healthcare facilities in the region. Europe is also among the major markets worldwide and the sales are expected to rise further owing to rising prevalence of psoriasis and arthritis patient population.
Fastest Growing Region
Asia Pacific region is poised to exhibit the fastest growth during the forecast period in the global Cosentyx drug market. Factors such as increasing healthcare spending, large untapped opportunities, growing medical tourism industry and rising disability-adjusted life years (DALYs) lost due to musculoskeletal disorders will aid the market expansion in Asia Pacific.
Get This Report in Japanese Language: ใณใปใณใใฃใฏในๅป่ฌๅๅธๅ ด
Get This Report in Korean Language: ์ฝ์ผํ ์ค ์์ฝํ ์์ฅ
About Author:
Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups.
(LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)
